Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007;4(1):17-24.
doi: 10.1016/j.ddmod.2007.10.003.

Mouse Models of Lipodystrophy Key reagents for the understanding of the metabolic syndrome

Ingrid Wernstedt Asterholm  1 , Nils Halberg, Philipp E Scherer
Affiliations

Mouse Models of Lipodystrophy Key reagents for the understanding of the metabolic syndrome

Ingrid Wernstedt Asterholm et al. Drug Discov Today Dis Models. 2007.

Abstract

Both the disproportionate loss of adipose tissue in the case of lipodystrophies and the disproportionate gain of adipose tissue in obesity are frequently associated with an increase in insulin resistance and its complications. Leptin replacement is a very promising therapeutic approach for the management of the complications of lipodystrophy. In contrast, leptin treatment for the reversal of obesity-related metabolic disorders has not proven to be successful. There is a need to better understand both of these phenomena. Mouse models of lipodystrophy may provide us with new pharmaceutical targets for the treatment and prevention of metabolic disturbances related to dysfunctional adipose tissue both in the context of lipodystrophy and obesity.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Metabolic Complications in Lipodystrophy
The underlying causes of lipodystrophy can be of many different origins. However, the more severe the liposdystrophy, the more severe are the metabolic complications. These complications may occur both as a consequence of dysfunctional adipocytes. The ensuing insulin resistance further aggravates the lipodystrophy phenotype.
See this image and copyright information in PMC

References

    1. Hegele RA, et al. Thematic review series: Adipocyte Biology. Lipodystrophies: windows on adipose biology and metabolism. J Lipid Res. 2007;48 (7):1433–1444. - PubMed
    1. Garg A. Adipose tissue dysfunction in obesity and lipodystrophy. Clin Cornerstone. 2006;8(Suppl 4):S7–S13. - PubMed
    1. Ebihara K, et al. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab. 2007;92 (2):532–541. - PubMed
    1. Javor ED, et al. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes. 2005;54 (7):1994–2002. - PubMed
    1. Shimomura I, et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev. 1998;12 (20):3182–3194. - PMC - PubMed

LinkOut - more resources